Randomized Trial Evaluating the Effectiveness of the General Practitioner Involvement in Cancer Screening Invitations
NCT ID: NCT02367001
Last Updated: 2015-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
53978 participants
INTERVENTIONAL
2014-02-28
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The hypothesis on which this project is based is that communication is probably more effective if the "receiver" feels personally targeted by invitation letters (Dear Martin, I am writing ...) and if he knows "the issuer "(his general practitioner rather an unknown person).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does the Recall by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?
NCT01279330
Evaluation of a New Invitation Procedure to the French Organized Colorectal Cancer Screening Program
NCT05589675
Influence of a Brief Intervention on CRC Screening
NCT02012829
Does the Invitation by the General Practitioner Improve Patients' Participation in Colorectal Cancer Screening?
NCT01279278
Promoting Cancer Screening Among Medicaid Recipients in Minnesota
NCT03275987
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1: standard invitation
Group 1: sending a standard invitation signed by the coordinating doctor (send by the structure responsible for organized screenings)
Intervention : Normal invitation
Normal invitation
No modification and signed by the coordinating doctor as usual
2: Revised invitation
Group 2: Sending a revised invitation ( text, layout) signed by the coordinating doctor (send by the structure responsible for organized screenings)
Intervention : revised invitation signed by the coordinating doctor
revised invitation signed by the coordinating doctor
Invitation with revised text and layout and signed by the coordinating doctor as usual
3 : revised invitation signed by the attending physician
Group 3: Sending a revised invitation signed by the attending physician (send by the structure responsible for organized screenings)
Intervention : Revised invitation signed by the attending physician
Revised invitation signed by the attending physician
signature typed or typed + handwritten
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Normal invitation
No modification and signed by the coordinating doctor as usual
revised invitation signed by the coordinating doctor
Invitation with revised text and layout and signed by the coordinating doctor as usual
Revised invitation signed by the attending physician
signature typed or typed + handwritten
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be affiliated to the following three health insurance companies: CPAM (Caisse Primaire d'Assurance Maladie), MSA (Mutualité Sociale Agricole), or RSI (Régime social des Indépendants)
* Having declared (to health insurance company) an attending physician who has given its written consent to participate in the study
* Present no exclusion criterion to cancer screening ( for each one)
* Be old from 50 to 74 years (breast and colorectal cancer) or from 25 to 65 years (cervical cancer)
25 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Tours
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ken HAGUENOER
Role: STUDY_DIRECTOR
University Hospital of TOURS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de Coordination des Dépistages des Cancers (CCDC)
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INCA-P3644-KH-GPs
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.